A Phase I Dose Escalation Study of Intermittent Oral OSI-906 dosing in Patients with Advanced Solid Tumors
Get More Information
Would you like more information about clinical trial sites that are recruiting participants for Study of Intermittent OSI-906 Dosing? Contact us by filling our your information to the right and we’ll respond to you.
MD Anderson Cancer Center
Houston, United States, 77030
Drug Development Unit, Royal Marsden Hospital
Sutton, United Kingdom, SM2 5PT